Cuur CURRICULUM VITAE Ingrid Vasiliu-Feltes, MD, EMBA, FAPA Date: 5/4/2016 Email: ivfeltes@med.miami.edu Education 2010-2011 Executive MBA, Health Sector Management and Policy, School of Business, University of Miami 1990-1996 MD, Carol Davila University, School of Medicine, Bucharest, Romania Board Certification Child and Adolescent Psychiatry, 2004, Certificate # 5735; recertified 4/21/14 Adult Psychiatry, 2012, Certificate # 51179; recertified 2/6/12 Medical Licensure 2007, State of Florida # ME 100771 2002-2008, State of Alabama # 24785 Current UHealth Positions: Chief Patient Safety and Quality Officer, University of Miami Health System Chief of Clinical Compliance and Quality Assurance, Department of Psychiatry Director, Clinical Trials Program 1
Past UHealth Positions Director, Managed Care Director, UHealth UMMG Clinic Professional Associations Membership American College of Healthcare Executives Academy of Medical Educators, University of Miami Beta Gamma Sigma International Honor Society American College of Psychiatrists American Psychiatric Association, Fellow Florida Psychiatric Society Awards and Honors 2014 Fellow of the American Psychiatric Association 2009 Sarah Esselstyn Howard Teaching Award, University of Miami, Miami, FL 2002-2003 Chief Resident,Columbia University, College of Physicians and Surgeons, NY,NY 2001 Award of Clinical Excellence in Research, Department of Psychiatry, SLRH, NY, Columbia University, College of Physicians and Surgeons 2
Committees Current Chair UHealth Patient Safety Council Committee for Review of Institutes/Centers at University of Miami Member UMH Patient Safety Committee UMMG Patient Safety Committee AOA/VBP Committee ICD 10/CDI Committee at University of Miami Pediatric Chair Search Committee Executive Committee, Department of Psychiatry UMMG Faculty Council UM Faculty Council UM Faculty Senate Alternate Pharmacy Clinical Review Committee, CMS Human Rights and Abuse Committee, Florida Psychiatric Society Legislative Committee, Florida Psychiatric Society U-Improve Committee Past UChart Implementation Task Force, University of Miami Information Resource Committee, University of Miami Pediatrics Ethics Committee, University of Miami Pharmacy Clinical Review Committee, CMS 3
Quality & Safety Skills Centers of Excellence Designation Joint Commission Accreditation Performance Improvement Infection Control Gap Analysis and Designed New Automated Reporting System Designed New Critical Results Reporting System Designed Executive Quality & Safety Dashboard Designed Quality & Safety Provider Scorecard Performed Analysis & PIP for Hospital and Physician Rankings Performed Gap Analysis & PIP for high impact Quality & Safety Metrics Chair of Patient Safety Council Chair of Quality Governance Council Chair of Patient Safety Council Administrative Skills Six Sigma Management Experience Clinical Systems Integration Experience State and national regulatory guidelines implementation and compliance for clinical, research and managed care Launched several large scale multidisciplinary initiatives to optimize outcomes Designed and implemented numerous clinical quality and safety programs to enhance and streamline quality reporting process Healthcare Analytics application for clinical, research and managed care operations Value based purchasing & Value based payment modifier performance improvement Joint Commission Accreditation/Reaccreditation Optimization IQR Performance Improvement CMS Star ranking HEDIS Measures Performance Improvement MU/PQRS Program NCQA Accreditation Process Center of Excellence Designation Process Improvement Improving Revenue Cycle/Denials Management 4
Clinical Research Administration Managed clinical research trial operating budgets Increased research portfolio Conducted clinical trial risk assessments Obtained IRB approval Provided oversight for compliance with all regulatory agencies Design and implementation strategies for clinical trials Provided oversight and leadership to clinical investigators Provided oversight for adherence to GCP and protocol design Standardized clinical research enterprise Created integrated research team Maintained quality standards in clinical trials research Provided oversight of human resource activities Enforced adherence to professional code of ethics Liaison with pharmaceutical industry Compliance and Quality Assurance Revised and monitored the implementation of a compliance and quality assurance program Developed and coordinated a multifaceted educational and training program that focuses on the elements of the compliance program Conducted periodic risk assessments and response plans Conducted internal monitoring and auditing of medical records Initiated quality improvement initiatives regarding clinical documentation Initiated and performed House-Staff Training for Billing & Documentation Managed Care Oversight during NCQA accreditation process Medical policy revisions and/or development Business contracts amendments Supervised and directed all activities related to Government Programs, as well other relevant accrediting bodies or regulatory agencies Provided medical expertise and oversight for all utilization review programs Supervised disease management programs 5
Supervised quality improvement program development and implementation Evaluated and modified medical decision-making procedures to control cost and increase quality of behavioral health services Participated and provided oversight in appeals and grievance process Provided oversight of the recruiting and credentialing process Provided oversight of all clinical peer review activities Managed physician relations and /or representation Supported clinical staff education Supported and develop strategic collaborative relationships with other business entities Chaired the Committees for Quality Management, Credentialing, Risk Management/Safety Developed behavioral guidelines for CMS Assessed and recommended strategies for compliance with regulatory requirements Implemented and monitored the outcomes of utilization review and disease management programs to meet quality and cost expectation Identified trends of over- and under-utilization and implemented actions plans Directed and oriented physicians in the correct application of approved guidelines Guided and enforced customer service standards per organizational guidelines Clinical Operations Planned, organized, managed and supervised the roles of clinicians Identified physician recruitment needs Collaborated in the hiring new staff members Established work schedules and assignments for medical staff Responsible for medical reviews and decisions as required for future planning Committees Current Chair Committee for Review of Institutes/Centers at University of Miami UHealth Patient Safety Council UHealth Quality Governance Council Member 6
ICD 10/CDI Committee at University of Miami Executive Committee, Department of Psychiatry UMMG Faculty Council UMMG leadership Council UM Faculty Senate Council Pharmacy Clinical Review Committee, CMS Human Rights and Abuse Committee, Florida Psychiatric Society Legislative Committee, Florida Psychiatric Society U-Improve Committee Past Risk Committee QI & PI Committee Senate Member UChart Implementation Task Force University of Miami Information Resource Committee Pediatrics Ethics Committee Pharmacy Clinical Review Committee, CMS Professional Training 07/2001-06/2003 Child and Adolescent Psychiatry Fellowship Columbia University, College of Physicians and Surgeons St. Luke s-roosevelt Hospital Center, NY, NY 07/1997-06/2001 Adult Psychiatry Residency Columbia University, College of Physicians and Surgeons St. Luke s-roosevelt Hospital Center, NY, NY Professional Experience -Academic Setting 1/1/2014-present Patient Safety and Quality Officer, UHealth 10/2012-present 7
Director of Clinical Trials Program Department of Psychiatry and Behavioral Sciences 05/2012-present Chief of Clinical Compliance and Quality Assurance, Department of Psychiatry and Behavioral Sciences 07/2011-04/2012 Medical Director, Managed Care University of Miami Behavioral Health 07/2008 06/20111 Medical Director UHealth Psychiatry, Coconut Grove 01/2007-06/2008 Grayson & Associates, P.C, Birmingham, AL Outpatient Psychiatry Trinity Hospital Center, Birmingham, AL, Inpatient Services, Detoxification & Consultation Services 07/2003-12/2006 Outpatient Psychiatry, Inpatient Services, Detoxification & Rehabilitation Services Mountain View Hospital, Gadsden, Alabama Professional Experience Private Sector 1994-1996 Manager, Swiss Red Cross, Eastern Europe Division 2012-present President, Executive Cortex Consulting, LLC President, Sports For Healthy Kids, Inc. 2013 Board Member, Southeast Region, NPHUSA 2013 Consulting Services, ChimeraCare, Inc. Consulting Services, Thelos Technology, Inc. 2015-present Athos Lab, LLC 8
ACADEMIC PORTFOLIO Academic Appointments Assistant Professor of Clinical Psychiatry, University of Miami, Miller School of Medicine Teaching Experience Medical Students 1999-2001, General Psychopharmacology, Columbia University, NY, NY 2008-2011, Eating Disorders, University of Miami Medical School, MS3 2008-2013, Autism, University of Miami Medical School, MS3 2012-2013, PBL Courses ( MD, MD/MPH tracks) 2012-2013, CBL Courses MS 1 2012-2013- Autism, Neurosciences Module University of Miami Medical School, MS1 2012-2013- Eating Disorders, Neurosciences Module University of Miami Medical School, MS1 2012-2013- Personality Disorders, Neurosciences Module, University of Miami Medical School, MS1 2012-2013- Small Group Review Cases, University of Miami Medical School, MS3 2011-2013 Ethics Small Group teaching, University of Miami 2014, Quality and Safety Metrics in Healthcare Psychology & Psychiatry Fellows Lectures 2001-2002, Psychopharmacology Class, Psychology Fellows, New York University 2002-2003, Psychopharmacology Class, Adult Psychiatry Residents, SLRH, NY, NY 2008, Gender Identity Disorder, Division of Child & Adolescent Psychiatry 9
2008, Attachment Disorders, Division of Child & Adolescent Psychiatry 2008, ODD & Conduct Disorder, Division of Child and Adolescent Psychiatry 2011-2013, Managed Care Lecture, Division of Child Psychiatry, PGY I & II Fellows 2011-2013, Establishing Private Practice, Division of Child Psychiatry, PGY II Fellows Seminars 2008-2013, Substance Abuse Seminar, Division of Child and Adolescent Psychiatry 2009-2013, Clinical Applications in Neuroimaging, Division of Child & Adolescent Psychiatry 2009-2013, Clinical Applications of Psychological Testing, Division of Child Psychiatry 2009-2011, Psychiatric Interview Skills Seminar, Division of Child Psychiatry 2011-2013, Medical Billing Compliance Seminar, University of Miami, FL 2013 CPT 2013 Changes and Billing Compliance Seminar, University of Miami Course Director 2011-2013, Child Development & Psychopathology, Child Psychiatry Fellowship 2012-2013, Healthcare Practice Management, Department of Psychiatry, PGY IV Professional Presentations-Academic Setting 2014 Quality and Safety Metrics in Healthcare, Faculty Presentations, UHealth Implementation Strategies for Quality and Safety Metrics, RN Workshop, UMH US News and World Report Health Rankings, Dean s Meeting, UHealth Center of Excellence Designations, Dean s Meeting,UHealth 2013 10
Billing & Coding Updates Sunovion Pharmaceuticals Preceptorship, Chair South Florida Mental Health Association, DSM 5 Provider Training Grand Rounds Presentation 2008, Latest Research and Clinical Implications in ADHD, Dept. of Psychiatry 2008, ADHD & Comorbid Disorders, Dept. of Child & Adolescent Psychiatry Columbia University, SLRHC, NY, NY 1997, Eating Disorders-Literature review 1998, Psychiatric Aspects of Temporal Lobe Seizures 1999, Neuroleptic Malignant Syndrome-Diagnosis and Treatment Grand Rounds Presentations, SLRHC, NY, NY 2001, Childhood Schizophrenia, An Update 2000, Transference and Countertransference-A Case of Psychoanalytic Psychotherapy 2000, Neuroimaging in Schizophrenia Psycho-Pharmacology Lectures 2004, Managing your patients optimally Seroquel (sponsored by Astra -Zeneca) 2004, Integrating Depakote ER into your Psychiatric Practice (sponsored by Abbott) 2005, Lamotrigine use in Pregnancy (sponsored by GlaxoSmithKline) 2005, Lamotrigine Use in Bipolar Depression (sponsored by Glaxo Smith Kline) 2006, Treatment Indications and Safety Profile for Symbyax (sponsored by Eli Lilly) 2006, Treatment options of comorbid ADHD (sponsored by Eli Lilly) 2006, Indications and safety profile for Focalin XR (sponsored by Novartis) 11
2007, Successfully managing your patients on Vyvanse ( sponsored by Shire) Other Presentations 2008, Miami ACEH, Maternal Suicide-Assessment and Prevention 2008, Gulliver Academy, Parent Association, Parenting in Today s Society 2009, Gulliver Academy, Teacher Workshop, Recognizing Learning Disabilities 2009, Gulliver Academy, Teacher Workshop, Classroom Interventions for Learning Disabilities Arnold Pfeffer Center for Neuro-Psychoanalysis, NY Psychoanalytic Institute Literature Review-Neuro-Imaging Evidence of AH Neuro-Imaging of the Striatum and Psychoanalytic Implications Neuro-Imaging of the Cingulate and Psychoanalytic Implications Special Skills/Training Buprenorphine License Extensive experience in Substance Abuse and Rehabilitation Services Extensive Experience in Emergency Psychiatry Elective Rotation in HIV/AIDS Psychiatry Elective Rotation in Pediatric Neurology Elective in Dialectic Behavioral Therapy 12
Research Portfolio 2014 Co-Investigator, A Randomized, Double-blind, Placebo-controlled, Parallel, 26- Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy, Envivo Co-Investigator, A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy, Envivo Co-Investigator, A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder, Alkermes: Co-Investigator, A 6-week randomized, parallel, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of Lurasidone in adolescent subjects with schizophrenia, Sunovion Co-Investigator: A 104-week, flexible-dose, open-label, multicenter, extension study to evaluate the long-term safety and effectiveness of Lurasidone in Pediatric subjects, Sunovion Co-Investigator, Geodon: A Phase 3, Multicenter, Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic) Alzheimer s Otsuka: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and 13
Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer s Type 2013 Principal Investigator, University of Miami, A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerated Principal Investigator, University of Miami, A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Setting Co-Investigator, University of Miami,EVP-6124-017: A multi-center 26-week extension study to evaluate the safety and clinical effects of prolonged exposure to 1 and 2 mg doses of EVP-6124, an Alpha-7 Nicotinic acetylcholine receptor agonist, as an adjunctive pro-cognitive treatment in subjects with chronic schizophrenia Co-Investigator, University of Miami,2 EVP-6124-016: A Randomized, Doubleblind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist (EVP 6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects Co-Investigator, University of Miami, Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients with Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone Co-Investigator, University of Miami, A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS) 14
2001 2000 2000 1999 Co-Investigator, University of Miami, e-caesar: Evaluation of a Cognitively Adaptive e-treatment in Schizophrenia-diagnosed Adults: A Remediation-based Approach. Co-Investigator, University of Miami, NN25307 - Phase III, multi-center, randomized, 12-week, double-blind,parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics Co-Investigator, University of Miami,WN25308 - A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with Subinvestigator, Adult Outpatient Psychiatry Division, SLRHC, NY, NY,Clinical Trial Evaluating the Combination of Fluoxetine and Olanzapine for Treatment Resistant Major Depression without Psychotic Features ( Funding by Eli Lilly & Co) Principal Investigator, PET Lab, Mount Sinai Hospital, NYC,White or Gray Matter Shrinkage in Schizophrenia Sub-Investigator, Neurobiological Disorders Service, SLRHC, NY, NY,MultiCenter Pilot Study to Examine the Clinical Effects of Cross Titration of Antipsychotics with Ziprasidone in Subjects with Schizophrenia or Schizoaffective Disorder, Followed by Open Extension Phase with Continued Ziprasodone Treatment( funding by Pfizer pharmaceuticals) 15
Subinvestigator, Neurobiological Disorders Service, SLRHC, NY, NY,Cost- Effectiveness and Functional Outcomes of Olanzapine in the Treatment of Schizophrenia : A Randomized Clinical Study ( Funding by Eli Lilly & Co) 16
17